Article

Mannheimia haemolytica leukotoxin binds to lipid rafts in bovine lymphoblastoid cells and is internalized in a dynamin-2- and clathrin-dependent manner.

Department of Pathobiological Sciences, University of Wisconsin, 2015, Linden Drive, West, Madison, WI 53706, USA.
Infection and Immunity (Impact Factor: 4.16). 11/2007; 75(10):4719-27. DOI: 10.1128/IAI.00534-07
Source: PubMed

ABSTRACT Mannheimia haemolytica is the principal bacterial pathogen of the bovine respiratory disease complex. Its most important virulence factor is a leukotoxin (LKT), which is a member of the RTX family of exotoxins produced by many gram-negative bacteria. Previous studies demonstrated that LKT binds to the beta(2)-integrin LFA-1 (CD11a/CD18) on bovine leukocytes, resulting in cell death. In this study, we demonstrated that depletion of lipid rafts significantly decreases LKT-induced bovine lymphoblastoid cell (BL-3) death. After binding to BL-3 cells, some of the LKT relocated to lipid rafts in an LFA-1-independent manner. We hypothesized that after binding to LFA-1 on BL-3 cells, LKT moves to lipid rafts and clathrin-coated pits via a dynamic process that results in LKT internalization and cytotoxicity. Knocking down dynamin-2 by small interfering RNA reduced both LKT internalization and cytotoxicity. Similarly, expression of dominant negative Eps15 protein expression, which is required for clathrin coat formation, reduced LKT internalization and LKT-mediated cytotoxicity to BL-3 cells. Finally, we demonstrated that inhibiting actin polymerization reduced both LKT internalization and LKT-mediated cytotoxicity. These results suggest that both lipid rafts and clathrin-mediated mechanisms are important for LKT internalization and cytotoxicity in BL-3 cells and illustrate the complex nature of LKT internalization by the cytoskeletal network.

0 Bookmarks
 · 
52 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aggregatibacter actinomycetemcomitans produces a repeats-in-toxin (RTX) leukotoxin (LtxA) that selectively kills human immune cells. Binding of LtxA to its β2 integrin receptor (lymphocyte function-associated antigen-1, LFA-1) results in the clustering of the toxin/receptor complex in lipid rafts. Clustering occurs only in the presence of LFA-1 and cholesterol, and LtxA is unable to kill cells lacking either LFA-1 or cholesterol. Here, the interaction of LtxA with cholesterol was measured using surface plasmon resonance and differential scanning calorimetry. The binding of LtxA to phospholipid bilayers increased by four orders of magnitude in the presence of 40% cholesterol relative to the absence of cholesterol. The affinity was specific to cholesterol and required an intact secondary structure. LtxA contains two cholesterol recognition/amino acid consensus (CRAC) sites; CRAC336 (333LEEYSKR339) is highly conserved among RTX toxins, while CRAC503 (501VDYLK505) is unique to LtxA. A peptide corresponding to CRAC336 inhibited the ability of LtxA to kill Jurkat (Jn.9) cells. Although peptides corresponding to both CRAC336 and CRAC503 bind cholesterol, only CRAC336 competitively inhibited LtxA binding to this sterol. A panel of full-length LtxA CRAC mutants demonstrated that an intact CRAC336 site was essential for LtxA cytotoxicity. The conservation of CRAC336 among RTX toxins suggests that this mechanism may be conserved among RTX toxins.
    Journal of Biological Chemistry 06/2013; DOI:10.1074/jbc.M113.486654 · 4.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Many pathogens hijack existing endocytic trafficking pathways to exert toxic effects in cells. Dynamin controls various steps of the intoxication process used by numerous pathogenic bacteria, viruses, and toxins. Targeting dynamin with pharmaceutical compounds may therefore have prophylactic potential. Here we review the growing number of pathogens requiring dynamin-dependent trafficking to intoxicate cells, outline the mode of internalization that leads to their pathogenicity, and highlight the protective effect of pharmacological and genetic approaches targeting dynamin function. We also assess the methodologies used to investigate the role of dynamin in the intoxication process and discuss the validity and potential pitfalls of using dynamin inhibitors (DIs) as therapeutics.
    Trends in cell biology 11/2012; DOI:10.1016/j.tcb.2012.10.007 · 12.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The number of antimicrobials available to treat bacterial respiratory disease in goats is extremely limited. Currently, only ceftiofur has been approved for use in this species. Concerns over the development of antimicrobial resistance in bacteria that infect humans have led to proposed restrictions on the use of this drug in food-producing animals. Tulathromycin, a triamilide macrolide antibiotic found to be safe and effective against respiratory bacterial pathogens in cattle and swine, was formulated to enhance persistence in lung tissue. The Minor Use Animal Drug Program (National Research Support Project-7) identifies and supports research directed at meeting the Food and Drug Administration (FDA) requirements for drug approval in minor species or for minor uses in major species. The current work was undertaken to support FDA approval of tulathromycin in the caprine species by providing an assessment of target animal drug safety, drug tissue elimination, and drug efficacy. Tulathromycin had no detrimental clinical effects, even in animals treated with 5X the proposed label dose for three times the proposed label duration. Tissue elimination and pharmacokinetic behavior paralleled that found in both cattle and swine. Efficacy analysis was conducted on the clinical effect and pharmacokinetic behavior of tulathromycin in goats as well as in vitro antimicrobial effects on bacterial isolates recovered from goats. Bacteria isolated from goats with clinical cases of pneumonia were highly susceptible to this drug in several in vitro assays. Overall, this research demonstrated that tulathromycin would be a safe, effective, and valuable medication in the treatment of bacterial pneumonia in goats.

Preview

Download
0 Downloads
Available from